HRP20151443T1 - Terapijsko sredstvo protiv stenoze kralježniäśnog kanala - Google Patents

Terapijsko sredstvo protiv stenoze kralježniäśnog kanala Download PDF

Info

Publication number
HRP20151443T1
HRP20151443T1 HRP20151443TT HRP20151443T HRP20151443T1 HR P20151443 T1 HRP20151443 T1 HR P20151443T1 HR P20151443T T HRP20151443T T HR P20151443TT HR P20151443 T HRP20151443 T HR P20151443T HR P20151443 T1 HRP20151443 T1 HR P20151443T1
Authority
HR
Croatia
Prior art keywords
spinal canal
stenosis
royal
channel
canal stenosis
Prior art date
Application number
HRP20151443TT
Other languages
English (en)
Croatian (hr)
Inventor
Keiichi Kuwano
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of HRP20151443T1 publication Critical patent/HRP20151443T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HRP20151443TT 2008-06-23 2009-06-22 Terapijsko sredstvo protiv stenoze kralježniäśnog kanala HRP20151443T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008162638 2008-06-23
EP09770106.4A EP2292231B1 (fr) 2008-06-23 2009-06-22 Agent thérapeutique pour la sténose du canal spinal
PCT/JP2009/061285 WO2009157396A1 (fr) 2008-06-23 2009-06-22 Agent thérapeutique pour la sténose du canal spinal

Publications (1)

Publication Number Publication Date
HRP20151443T1 true HRP20151443T1 (hr) 2016-01-29

Family

ID=41444462

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151443TT HRP20151443T1 (hr) 2008-06-23 2009-06-22 Terapijsko sredstvo protiv stenoze kralježniäśnog kanala

Country Status (15)

Country Link
US (1) US8629145B2 (fr)
EP (1) EP2292231B1 (fr)
JP (1) JP5527205B2 (fr)
KR (1) KR101626168B1 (fr)
CN (3) CN105168218A (fr)
CA (1) CA2728089C (fr)
CY (1) CY1117080T1 (fr)
DK (1) DK2292231T3 (fr)
ES (1) ES2557303T3 (fr)
HR (1) HRP20151443T1 (fr)
HU (1) HUE025885T2 (fr)
PL (1) PL2292231T3 (fr)
PT (1) PT2292231E (fr)
SI (1) SI2292231T1 (fr)
WO (1) WO2009157396A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246336B1 (fr) * 2008-02-28 2020-07-01 Nippon Shinyaku Co., Ltd. Inhibiteur de fibrose
SG176915A1 (en) 2009-06-26 2012-01-30 Nippon Shinyaku Co Ltd Crystals
WO2011024874A1 (fr) * 2009-08-26 2011-03-03 日本新薬株式会社 Sels d'addition avec une base
SG11201804320QA (en) 2015-12-02 2018-06-28 Nippon Shinyaku Co Ltd Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
CN109563055B (zh) * 2016-07-29 2021-12-24 成都苑东生物制药股份有限公司 氨基吡嗪类化合物或盐、异构体、其制备方法及用途
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
MX2020007315A (es) 2017-09-28 2020-08-20 Nippon Shinyaku Co Ltd Cristal.
AR113882A1 (es) 2017-11-16 2020-06-24 Nippon Shinyaku Co Ltd Preparación de liberación controlada
US10407396B2 (en) * 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
WO2020157730A1 (fr) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal Composition pharmaceutique à libération contrôlée de sélexipag ou son métabolite actif
PH12022550380A1 (en) * 2019-08-19 2023-03-13 Nippon Shinyaku Co Ltd Salt
JP7646646B2 (ja) 2019-10-23 2025-03-17 日本新薬株式会社 セレキシパグを含む医薬組成物
JP2023512273A (ja) 2020-01-31 2023-03-24 アクテリオン ファーマシューティカルズ リミテッド 制御放出セレキシパグ組成物
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
TW202304444A (zh) * 2021-03-31 2023-02-01 日商日本新藥股份有限公司 步行障礙治療劑
JP7010404B1 (ja) 2021-03-31 2022-02-10 日本新薬株式会社 歩行障害治療剤
WO2023131608A1 (fr) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Compositions à libération contrôlée
WO2023214059A1 (fr) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Composés de diphénylpyrazine utilisés en tant que promédicaments
WO2024017964A1 (fr) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable comprenant un dérivé de diphénylpyrazine
WO2024133620A1 (fr) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd Test de dissolution in vitro
WO2024194449A1 (fr) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Composition pharmaceutique comprenant un dérivé de diphénylpyrazine
WO2025196095A1 (fr) 2024-03-20 2025-09-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable pour le traitement de l'hypertension pulmonaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (fr) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
KR100663147B1 (ko) * 2002-02-19 2007-02-28 오노 야꾸힝 고교 가부시키가이샤 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제
HUE029417T2 (en) 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
EP2246336B1 (fr) * 2008-02-28 2020-07-01 Nippon Shinyaku Co., Ltd. Inhibiteur de fibrose

Also Published As

Publication number Publication date
CN102065863A (zh) 2011-05-18
JPWO2009157396A1 (ja) 2011-12-15
CN103690541A (zh) 2014-04-02
EP2292231B1 (fr) 2015-10-21
SI2292231T1 (sl) 2016-03-31
WO2009157396A1 (fr) 2009-12-30
ES2557303T3 (es) 2016-01-25
KR101626168B1 (ko) 2016-05-31
PL2292231T3 (pl) 2016-03-31
CY1117080T1 (el) 2017-04-05
US20110105518A1 (en) 2011-05-05
EP2292231A1 (fr) 2011-03-09
EP2292231A4 (fr) 2012-03-28
US8629145B2 (en) 2014-01-14
DK2292231T3 (en) 2015-12-14
PT2292231E (pt) 2015-12-31
JP5527205B2 (ja) 2014-06-18
CN105168218A (zh) 2015-12-23
CA2728089A1 (fr) 2009-12-30
KR20110033125A (ko) 2011-03-30
CA2728089C (fr) 2017-04-11
HUE025885T2 (en) 2016-05-30

Similar Documents

Publication Publication Date Title
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
HRP20201243T1 (hr) N-piperidinil acetamidni derivati kao blokatori kalcijevog kanala
HRP20201352T1 (hr) Inhibitor fibroze
IL201796A (en) Indole-3-Inglet or its pharmaceutical salts for use in the treatment of dermal lesion caused by papillomavirus
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
WO2008096775A1 (fr) Agent thérapeutique pour la douleur
WO2011146808A3 (fr) Formulation topique pour inhibiteur de jak
WO2005091991A3 (fr) Procedes d'utilisation et compositions comprenant des composes destines au traitement et a la gestion de maladies ou de troubles de la peau
WO2014120808A8 (fr) Pyridone amides comme modulateurs des canaux sodiques
WO2007093450A3 (fr) Derives de catecholamine deuteries et medicaments comprenant de tels composes
HRP20250703T1 (hr) Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil) – fenola
DK2451445T3 (da) Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
IL228904A0 (en) Use of milankiperan, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
NZ605469A (en) Nalbuphine-based formulations and uses thereof
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
HRP20100577T1 (hr) Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti
WO2008052139A3 (fr) Doxepine à dose ultrafaible, et ses procédés d'utilisation pour traiter des troubles du sommeil
JP2015518007A5 (fr)
IL198180A (en) Salt p- toluene 5-amino-3-sulfonic acid (2'-0-acetyl-3'-deoxy-ß-d-riboforanosyl) -3h-thiazole [5,4- d] pyrimidine-2-on crystalline form , A pharmaceutical product containing it, its use in the preparation of a drug and methods for its manufacture
WO2007136741A3 (fr) N-desméthyldoxépine et procédés pour traiter les troubles du sommeil l'utilisant
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
CA2736751A1 (fr) Sels de n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide
TW200716204A (en) Pharmaceutical composition
WO2012024583A3 (fr) Composés oxystérol